Intelligence Feed event · Equity · 2026-09-12

    Eli Lilly immunology sales reach $2.6B in H1 2026 led by Taltz, Ebglyss, and Omvoh

    Question

    Eli Lilly immunology sales reach $2.6B in H1 2026 led by Taltz, Ebglyss, and Omvoh

    Direct answer

    Eli Lilly disclosed that its immunology franchise generated $2.6 billion in revenue during the first half of 2026, representing 9% year-over-year growth and contributing 6.1% of consolidated net sales. Growth was anchored by anchor asset Taltz alongside commercial adoption of newly launched therapies Ebglyss and Omvoh. The franchise is pursuing a multi-asset diversification strategy to complement Eli Lilly's dominant incretin/GLP-1 portfolio. Growth is underpinned by external business development, including the integrations of DICE Therapeutics, Morphic Therapeutic, and Merida.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-12
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Eli Lilly immunology sales reach $2.6B in H1 2026 led by Taltz, Ebglyss, and Omvoh”, revision 1, evidence through 2026-09-12. https://marketontology.com/market-events/2026-09-12/eli-lilly-immunology-sales-reach-2-6b-in-h1-2026-led-by-taltz-ebglyss-and-omvoh-203d7c

    EQUITY
    Eli Lilly immunology sales reach $2.6B in H1 2026 led by Taltz, Ebglyss, and Omvoh
    Eli Lilly disclosed that its immunology franchise generated $2.6 billion in revenue during the first half of 2026, representing 9% year-over-year growth and contributing 6.1% of consolidated net sales. Growth was anchored by anchor asset Taltz alongside commercial adoption of newly launched therapies Ebglyss and Omvoh. The franchise is pursuing a multi-asset diversification strategy to complement Eli Lilly's dominant incretin/GLP-1 portfolio. Growth is underpinned by external business development, including the integrations of DICE Therapeutics, Morphic Therapeutic, and Merida.
    LLYABBV
    Impact
    64
    SEP 12
    SIG
    85%
    LLYABBV
    Eli Lilly immunology sales reach $2.6B in H1 2026 led by Taltz, Ebglyss, and Omvoh
    Eli Lilly disclosed that its immunology franchise generated $2.6 billion in revenue during the first half of 2026, representing 9% year-over-year growth and contributing 6.1% of consolidated net sales. Growth was anchored by anchor asset Taltz alongside commercial adoption of newly launched therapies Ebglyss and Omvoh. The franchise is pursuing a multi-asset diversification strategy to complement Eli Lilly's dominant incretin/GLP-1 portfolio. Growth is underpinned by external business development, including the integrations of DICE Therapeutics, Morphic Therapeutic, and Merida.
    → Commercial scaling of immunology therapies Ebglyss and Omvoh expands LLY revenue diversity beyond GLP-1 metabolic franchise cash flows.
    Impact
    Eli Lilly disclosed that its immunology franchise generated $2.6 billion in revenue during the first half of 2026, representing 9% year-over-year growth and contributing 6.1% of consolidated net sales. Growth was anchored by anchor asset Taltz alongside commercial adoption of newly launched therapies Ebglyss and Omvoh. The franchise is pursuing a multi-asset diversification strategy to complement Eli Lilly's dominant incretin/GLP-1 portfolio. Growth is underpinned by external business development, including the integrations of DICE Therapeutics, Morphic Therapeutic, and Merida.
    Affected
    LLYABBV
    Transmission
    Commercial scaling of immunology therapies Ebglyss and Omvoh expands LLY revenue diversity beyond GLP-1 metabolic franchise cash flows.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYnon-incretin biopharma revenue diversificationUp1-3mImmunology revenue increased 9% YoY to $2.6B in H1 2026 with expanding commercial uptake of Ebglyss and Omvoh.
    ABBVimmunology market share competitionMixed1-3mGrowth in LLY's Ebglyss and Omvoh targets dermatology and gastroenterology segments where AbbVie maintains major exposure.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month